Bio Asia Taiwan 2026

Event description:

If you're attending Bio Asia Taiwan 2026, let’s connect. Our team will be meeting with biotech and pharma companies to discuss clinical development strategies across Asia-Pacific and globally. Whether you're planning a first-in-human study, exploring regional development options, preparing for partnering discussions, or looking ahead to commercialization, we'd be happy to discuss your program and share our experience.

We'll also be sharing insights on Australia as a destination for clinical trials, including how sponsors can generate early clinical data efficiently and use those results to inform broader APAC and global development strategies. These approaches are being applied across a range of innovative therapies, including ADCs, cell therapies, RNA therapeutics, functional peptides, and obesity programs.

Presentation:

Speaker: Daniela Caiazza, PhD.

Topic: Australia: A Go-To Destination for Clinical Trials.

Join Daniela as she explores why Australia continues to be a popular destination for early clinical development and how sponsors are using the country's regulatory and funding advantages to accelerate their programs.

Novotech Attendees:

• Andy Liu 刘寒松, Managing Director, Greater China and Global Labs
• Xiaoming Zhang, DBA 张晓鸣, Vice President, Head of Business Development, APAC
• Calvin Tzeng 曾宣凱, Business Development Director
• Angel Ching 井立捷, Business Development Director
• Ming Lee 李明峻, Senior Business Development Manager
• Martin Guan 管一青, Head of Lab Novotech.

Schedule a meeting with our team or visit Booth M509 to discuss your upcoming clinical development plans.